Taysha Gene Therapies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-129.88	-109	-89.3	-111.57	-166.01	-174.52
Depreciation & Amortization	1.16	1.15	1.25	1.37	1.17	0.49
Stock-Based Compensation	15.55	13.3	13.1	7.91	18.04	18.18
Other Adjustments	3.54	6.83	6.19	47.28	39.89	10.14
Changes in Accounts Payable	0.21	-0.15	-2.92	-2.3	-7.8	14.49
Changes in Accrued Expenses	3.27	6.29	-1.42	-6.28	-9.32	17.54
Changes in Unearned Revenue	-7.47	-9.77	-8.33	-15.45	33.56	-
Changes in Other Operating Activities	-1.48	-1.73	0.21	6.01	2.09	-3.37
Operating Cash Flow	-111.95	-93.09	-81.23	-73.02	-88.39	-117.04
Capital Expenditures	-0.38	-0.74	-0.37	-3.87	-20.62	-15.3
Purchases of Intangible Assets	-3	-	-	-3.5	-4.25	-6.25
Other Investing Activities	0.13	0.13	0.01	0.02	-0.06	-
Investing Cash Flow	-3.26	-0.6	-0.36	-7.35	-24.93	-21.55
Long-Term Debt Issued	-	49.85	-	39.55	-	39.96
Long-Term Debt Repaid	-	-40.61	-	-43	-	-
Net Long-Term Debt Issued (Repaid)	-	9.24	-	-3.45	-	39.96
Issuance of Common Stock	109.36	265.69	76.87	140.86	53.5	-
Net Common Stock Issued (Repurchased)	109.36	265.69	76.87	140.86	53.5	-
Other Financing Activities	-0.22	-0.34	-0.19	-1.02	-1.4	-0.87
Financing Cash Flow	275.35	274.59	76.68	136.39	52.1	39.08
Net Cash Flow	160.15	180.9	-4.9	56.02	-61.22	-99.51
Free Cash Flow	-112.33	-93.83	-81.6	-76.89	-109.01	-132.35
FCF Margin	-1503.57%	-960.07%	-979.23%	-497.62%	-4356.87%	-
Free Cash Flow Per Share	-0.33	-0.29	-0.33	-0.66	-2.48	-3.52
Levered Free Cash Flow	-134.57	-104.72	-100.89	-135.53	-166.94	-120.71
Unlevered Free Cash Flow	-137.26	-115.46	-103.06	-92.95	-163.38	-159.41

SEC Filings: 10-K · 10-Q